Claire Friedman, MD is an assistant attending in the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer, with an additional appointment in the Phase 1 Early Drug Development service. She is engaged in the development of new treatment paradigms for gynecologic cancers that incorporate checkpoint blockade and other immune-based strategies, as well as spearheading efforts within her service to examine mechanisms of checkpoint blockade resistance. Dr. Friedman also is one of the clinical leads for MSK-SPECTRUM, a multi-modal prospective study of spatio-temporal determinants of tumor evolution, treatment and response in high grade serous ovarian cancer.
